Tozasertib (VX-680, MK-0457)

For research use only. Not for use in humans.

目录号：S1048 中文名称：陶扎色替

Tozasertib (VX-680, MK-0457) Chemical Structure

CAS No. 639089-54-6

Tozasertib (VX-680, MK-0457)是一种pan-Aurora抑制剂，对Aurora A作用最强，无细胞试验中K_iapp为0.6 nM，而对Aurora B/Aurora C的作用较弱，对Aurora A选择性比其他55种激酶高100倍。唯二的例外是 Fms-related tyrosine kinase-3 (FLT-3) 和 c-ABL tyrosine kinase，也可被 Tozasertib 抑制，对应的Ki值分别为30 nM和20 nM。Tozasertib 可诱导凋亡和自噬。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1098.34	现货
25mg	RMB 1211.51	现货
100mg	RMB 3017.92	现货
250mg	RMB 3833.09	现货
300mg	RMB 4316.13	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Tozasertib (VX-680, MK-0457)发表文献88篇：

Nature, 2018, 559(7713):211-216.

PubMed: 29973724 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cell, 2010, 6;142(3):444-55.

PubMed: 20691903 ( click the link to review the publication )

J Clin Invest, 2020, 139080

PubMed: 33016928 ( click the link to review the publication )

EMBO Rep, 2020, 3;21(4):e49700

PubMed: 32030856 ( click the link to review the publication )

Cancer Res, 2020, 80(18):3841-3854

PubMed: 32690724 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(4):1008-1017

PubMed: 31848297 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa103

PubMed: 32617558 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31652588 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):432

PubMed: 31160567 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Analyst, 2019, 145(1):97-106

PubMed: 31746831 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, doi: 101016/jjpba2019112962

PubMed: 31711864 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Cell Signal, 2018, 52:137-146

PubMed: 30223016 ( click the link to review the publication )
SLAS Discov, 2018, 23(2):132-143

PubMed: 28957641 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):1004-1010

PubMed: 30080692 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29560108 ( click the link to review the publication )

Neuron, 2017, 94(6):1142-1154

PubMed: 28641113 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Oncogene, 2017, 36(44):6177-6189

PubMed: 28869606 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

EMBO J, 2016, 35(8):803-19

PubMed: 26929011 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(50):14366-14371

PubMed: 28182563 ( click the link to review the publication )

Elife, 2016, 5:e11402

PubMed: 26878753 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):153-66

PubMed: 27138904 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):819-26

PubMed: 27373675 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(1):212-8

PubMed: 27003257 ( click the link to review the publication )

Exp Hematol, 2016, 44(3):189-93

PubMed: 26706195 ( click the link to review the publication )

Tumour Biol, 2016, 37(11):14745-14755

PubMed: 27629142 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )
Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5338-48

PubMed: 26152738 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(2):419-28

PubMed: 25522764 ( click the link to review the publication )

Oncol Rep, 2015, 34(2):803-10

PubMed: 26044736 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0134306

PubMed: 26218638 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(6):1354-64

PubMed: 25873592 ( click the link to review the publication )

J Mol Cell Biol, 2014, 6(3):240-54

PubMed: 24847103 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2014, 307(2):L173-85

PubMed: 24838752 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

Oncol Lett, 2014, 7(1):121-124

PubMed: 24348832 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7498-511

PubMed: 25115395 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Arthritis Rheum, 2013,

PubMed: 23653330 ( click the link to review the publication )

Mol Cancer Res, 2013, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(11):1326-36

PubMed: 24008673 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1235-46

PubMed: 23321637 ( click the link to review the publication )

J Cell Mol Med, 2013, 17(2):265-76

PubMed: 23301855 ( click the link to review the publication )

Vet Comp Oncol, 2013, 10.1111/vco.12018

PubMed: 23410058 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23328114 ( click the link to review the publication )
Eur J Cancer, 2012, 48(15):2417-30

PubMed: 22244830 ( click the link to review the publication )

Oncogene, 2012, 31(31):3584-96

PubMed: 22120720 ( click the link to review the publication )

J Med Chem, 2012, 55(17):7392-416

PubMed: 22803810 ( click the link to review the publication )

Brain Pathol, 2012, 23(3):244-53

PubMed: 22971244 ( click the link to review the publication )

J Neurosci, 2012, 32(32):11050-66

PubMed: 22875938 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1217-28

PubMed: 22306067 ( click the link to review the publication )

Biochem J, 2012, 447(1):93-102

PubMed: 22784093 ( click the link to review the publication )

Exp Cell Res, 2012, 318(4):336-49

PubMed: 22197704 ( click the link to review the publication )

Cytoskeleton, 2012, 69(10):840-53

PubMed: 22887753 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Curr Biol, 2011, 21(16):1356-65

PubMed: 21820309 ( click the link to review the publication )

Cancer Res, 2011, 71(23):7207-15

PubMed: 21978935 ( click the link to review the publication )

J Biol Chem, 2011, 286(42):36304-15

PubMed: 21878642 ( click the link to review the publication )

Biochem J, 2011, 440(1):85-93

PubMed: 21774789 ( click the link to review the publication )

Mol Cancer Ther, 2010, 9(5):1318-27

PubMed: 20388735 ( click the link to review the publication )

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述

靶点

Aurora A ^[1] (Cell-free assay)	Aurora C ^[1] (Cell-free assay)	Aurora B ^[1] (Cell-free assay)	FLT3 ^[4] (Cell-free assay)	Bcr-Abl ^[4] (Cell-free assay)
0.6 nM(Ki app)	4.6 nM(Ki app)	18 nM(Ki app)	30 nM(Ki)	30 nM(Ki)

体外研究

虽然VX-680具有多激酶特性，VX-680却诱导相似的细胞毒性，IC50约为300 nM，在G2/M期，核内复制期，及转染ABL或FLT-3激酶的BaF3细胞凋亡时，显示一个Aurora B 类似的抑制表现型。VX-680抑制CAL-62细胞增殖，这种作用存在时间依赖性。用VX-680处理14天，明显降低群体的数量和大小，处理8305C下降达到70%，处理CAL-62, 8505C,和BHT-101下降达到90%。用VX-680处理不同ATC细胞，抑制细胞增殖，IC50为25到150 nM，这种作用存在时间和剂量依赖性。在软琼脂中，VX-680明显削弱不同细胞系形成群落的能力。caspase-3的活性分析显示VX-680诱导不同细胞凋亡。VX-680处理CAL-62 细胞12小时，形成DNA含量≥4N细胞累积物。微速摄影分析显示VX-680处理的CAL-62细胞离开细胞中期。VX-680可以抑制组蛋白H3的磷酸化作用。^[2] VX-680作用于携带T315I突变的BCR-Abl的病人样本，具有明显抑制活性。^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BE-13	MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\xPIppUUN3ME2wMlAxOzN6IN88US=>	NWjDXpBJW0GQR2LFVi=>
RS4-11	M{XNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTiTWM2OD1yLkCwOFA1KM7:TR?=	M2\ZW3NCVkeURWK=
MFH-ino	MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;vTWM2OD1yLkCwPVkh\|ryP	MW\TRW5IWkWU
NTERA-S-cl-D1	NF;MNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMEG0N\|Qh\|ryP	NUnRR4lZW0GQR2LFVi=>
697	MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3O4TWlEPTB;MD6wNlQ4OSEQvF2=	M3;JcHNCVkeURWK=
NALM-6	M{\LWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvwUoJYUUN3ME2wMlAzPTV{IN88US=>	NXLwTpZFW0GQR2LFVi=>
ES8	NFjtTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMES2NVMh\|ryP	M3rob3NCVkeURWK=
HUTU-80	NGDIPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMEWyPVkh\|ryP	NVuyNnQyW0GQR2LFVi=>
MV-4-11	NES4epFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGns[mpKSzVyPUCuNFc4QDJizszN	MnfkV2FPT1KHUh?=
MONO-MAC-6	M2LsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{n4fGlEPTB;MD6wO\|g4QSEQvF2=	NGrZVZpUSU6JUlXS
LC-2-ad	NVf4[WNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfqZ4xKSzVyPUCuNFg4QDlizszN	MWHTRW5IWkWU
BL-41	M{fh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4P6NGlEPTB;MD6xNFQ1PSEQvF2=	MoTaV2FPT1KHUh?=
A4-Fuk	NFi1V4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMUG1OlMh\|ryP	NFH6Z49USU6JUlXS
SW954	M3Hidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFW2PFFKSzVyPUCuNVIzOjlizszN	MWfTRW5IWkWU
BV-173	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{[5XWlEPTB;MD6xNlY1OSEQvF2=	M4PvUnNCVkeURWK=
TE-11	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfFTWM2OD1yLkG0PVgzKM7:TR?=	NXLWTIJuW0GQR2LFVi=>
SK-UT-1	M{TZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mke2TWM2OD1yLkG1PVY2KM7:TR?=	MVPTRW5IWkWU
SIG-M5	M{fBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrOeJpKSzVyPUCuNVY4ODdizszN	MWPTRW5IWkWU
OCUB-M	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTCWmxRUUN3ME2wMlE3QTh\|IN88US=>	MnTnV2FPT1KHUh?=
K052	Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\Ye2lEPTB;MD6xPVQ5KM7:TR?=	NYjGZ2txW0GQR2LFVi=>
VA-ES-BJ	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPGcphKSzVyPUCuNlAxQDZizszN	MYDTRW5IWkWU
SW982	M3HJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmWyTWM2OD1yLkKxN\|gh\|ryP	MV7TRW5IWkWU
LB647-SCLC	NX:0NXY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYraZpFVUUN3ME2wMlIyPTJ\|IN88US=>	MXLTRW5IWkWU
PSN1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfqTWM2OD1yLkKyNFI3KM7:TR?=	MXXTRW5IWkWU
BB30-HNC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXKxOVhNUUN3ME2wMlIzPTlzIN88US=>	MkfMV2FPT1KHUh?=
ST486	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HyXGlEPTB;MD6yN\|A5PyEQvF2=	MXLTRW5IWkWU
MOLT-4	M4XjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYr3SHlqUUN3ME2wMlI{OzN5IN88US=>	MWrTRW5IWkWU
EW-16	Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFW5WXFKSzVyPUCuNlM4PjhizszN	MYXTRW5IWkWU
KS-1	NWS4bG9JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HiO2lEPTB;MD6yN\|c5PSEQvF2=	NXLXeph6W0GQR2LFVi=>
SR	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXvTWM2OD1yLkK0OVY1KM7:TR?=	M1ywOnNCVkeURWK=
KM12	NVzEcJFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvOPJJ5UUN3ME2wMlI3OzZizszN	MlfEV2FPT1KHUh?=
EM-2	Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTsUJpwUUN3ME2wMlI3PjRzIN88US=>	MX3TRW5IWkWU
MEG-01	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYD5SoJuUUN3ME2wMlI4QDR7IN88US=>	NFH3ZWNUSU6JUlXS
NB13	MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMke5PFQh\|ryP	NHrYOIlUSU6JUlXS
RKO	NUHTXm42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwM{C4NVMh\|ryP	NXPteohlW0GQR2LFVi=>
CESS	M{P1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwM{GzNlgh\|ryP	NYnTfohyW0GQR2LFVi=>
EoL-1-cell	NVvmW\|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\lXJJKSzVyPUCuN\|M1PTlizszN	M2\KVXNCVkeURWK=
DOHH-2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwM{O3PFEh\|ryP	Mn:wV2FPT1KHUh?=
A388	NVj4RVhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFv1eHlKSzVyPUCuN\|QxQDZizszN	MUHTRW5IWkWU
LAMA-84	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUS4XnRLUUN3ME2wMlM2OTd6IN88US=>	NXniWYd7W0GQR2LFVi=>
IMR-5	NWPvVmlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzQSIw6UUN3ME2wMlM2PTRizszN	NGrJfpZUSU6JUlXS
KARPAS-422	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX:zTVlJUUN3ME2wMlM4Ojd{IN88US=>	NXfCTnh2W0GQR2LFVi=>
MRK-nu-1	NIXRd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwM{ixN{DPxE1?	NYLYd2lNW0GQR2LFVi=>
BL-70	NE\3VXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwM{i5O\|Qh\|ryP	NHPqVVVUSU6JUlXS
LXF-289	NWrTPZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Xn[GlEPTB;MD60NFQxPiEQvF2=	M2rGVXNCVkeURWK=
RL95-2	MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jkeGlEPTB;MD60NFU3PyEQvF2=	MmHNV2FPT1KHUh?=
QIMR-WIL	M3jhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrCTWM2OD1yLkSyOlc3KM7:TR?=	MXHTRW5IWkWU
K-562	M2m3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXzVJU4UUN3ME2wMlQ{PDd{IN88US=>	M{HRUnNCVkeURWK=
NCI-H510A	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknuTWM2OD1yLkSzPFI{KM7:TR?=	NYjxTmVYW0GQR2LFVi=>
NCI-H524	NX7SR5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHu[GZKSzVyPUCuOVEyPDdizszN	MYHTRW5IWkWU
KE-37	M2\WWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPQ[IJLUUN3ME2wMlUzOTB{IN88US=>	MYjTRW5IWkWU
KP-N-YS	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\wblFIUUN3ME2wMlU1Ozl{IN88US=>	NEGycXJUSU6JUlXS
LS-411N	MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\LSodbUUN3ME2wMlU4PzV{IN88US=>	MoeyV2FPT1KHUh?=
CTV-1	MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwNUi3O\|Mh\|ryP	M2XyfHNCVkeURWK=
NCI-SNU-16	M1u4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3hVIJSUUN3ME2wMlY{PTdzIN88US=>	Mlm2V2FPT1KHUh?=
HT-144	MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXITWM2OD1yLk[zO\|k5KM7:TR?=	NXu2V28xW0GQR2LFVi=>
NCI-H187	MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PEdWlEPTB;MD62OFE{KM7:TR?=	M2TSenNCVkeURWK=
OCI-AML2	M1XXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\i[29ZUUN3ME2wMlY1PDB\|IN88US=>	MnPkV2FPT1KHUh?=
CCRF-CEM	NH7ISGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFO2fYhKSzVyPUCuOlU{PDZizszN	MnTOV2FPT1KHUh?=
ONS-76	M4foSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwNk[0OVgh\|ryP	MWDTRW5IWkWU
IST-SL2	MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvkNW9KSzVyPUCuO\|E6QDJizszN	MUfTRW5IWkWU
NB6	Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwN{eyOVQh\|ryP	NUPMVVFkW0GQR2LFVi=>
SK-PN-DW	MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7JS3RsUUN3ME2wMlc6OTRizszN	MmS1V2FPT1KHUh?=
HCC1599	NIe4cFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\lZlV4UUN3ME2wMlgxQDd2IN88US=>	MVfTRW5IWkWU
MC116	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXSPHpKSzVyPUCuPFUxOTFizszN	NUOyeZNyW0GQR2LFVi=>
TE-15	NWX3V49rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwOEWwPVgh\|ryP	M3XNfnNCVkeURWK=
HOP-62	MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwOE[zNlkh\|ryP	M3j1eHNCVkeURWK=
TGBC24TKB	NGi5enFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jNNGlEPTB;MD64OlM5PSEQvF2=	NYrvU3RGW0GQR2LFVi=>
HCE-4	MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLlc29KSzVyPUCuPFgxPjNizszN	NV:x[mR4W0GQR2LFVi=>
ALL-PO	NYLyXJA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Tp[mlEPTB;MD64PFE4PSEQvF2=	M1;VPXNCVkeURWK=
KGN	Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vDe2lEPTB;MD64PVk6PSEQvF2=	MVrTRW5IWkWU
ML-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\VS4NKSzVyPUCuPVAzPTlizszN	MVHTRW5IWkWU
ES4	M2nIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwOUGxNlgh\|ryP	NFSzUW9USU6JUlXS
SF126	NFrPS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrhTWM2OD1yLkm0PFE6KM7:TR?=	MYLTRW5IWkWU
SK-N-DZ	NIT4VmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1r3VWlEPTB;MD65OlE5QSEQvF2=	NXvh[pZHW0GQR2LFVi=>
HCC1187	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPK[5BKSzVyPUGuNFA2ODVizszN	NXXPOGxpW0GQR2LFVi=>
DU-4475	NFvKNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUL5e445UUN3ME2xMlAyPzV4IN88US=>	NHOw[oRUSU6JUlXS
NKM-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXr3OpVmUUN3ME2xMlAzPzd3IN88US=>	NVjEU4dqW0GQR2LFVi=>
HL-60	NXzHbGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PHU2lEPTB;MT6wOlU4PCEQvF2=	MV;TRW5IWkWU
SBC-1	M3zVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;WTWM2OD1zLkGyOVQzKM7:TR?=	NXTvZ45qW0GQR2LFVi=>
TE-10	NXr3NYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;t[mlEPTB;MT6xNlk1PiEQvF2=	MX7TRW5IWkWU
ETK-1	M4W3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzZTWM2OD1zLkGzOlE{KM7:TR?=	MXLTRW5IWkWU
HAL-01	NUnqV2VoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTKdo1KSzVyPUGuNVY4ODlizszN	NXrsTld3W0GQR2LFVi=>
BB65-RCC	MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XEc2lEPTB;MT6xPFAxPSEQvF2=	NEW1UY1USU6JUlXS
EW-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHRNIdKSzVyPUGuNVg2PjJizszN	NXvrfG1QW0GQR2LFVi=>
SK-NEP-1	NYXsS4RUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTFwMkGxNVEh\|ryP	MmXuV2FPT1KHUh?=
SK-LMS-1	NXzsfGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTFwMkKyNVIh\|ryP	MVTTRW5IWkWU
DEL	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnnVllCUUN3ME2xMlI2PjR\|IN88US=>	NUWxc\|NsW0GQR2LFVi=>
GT3TKB	NYXj[IJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFwMkiwOVch\|ryP	M4f2fnNCVkeURWK=
MOLT-16	M4r4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mof6TWM2OD1zLkO1OFA2KM7:TR?=	NUDNUHNtW0GQR2LFVi=>
CMK	M{nEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXQVFhKSzVyPUGuOFIyOTdizszN	NXfuNHZ4W0GQR2LFVi=>
NB5	NHjnWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXXPYxKSzVyPUGuOlQzOjlizszN	NX;1bXBQW0GQR2LFVi=>
NCI-H1963	M4\EWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkKyTWM2OD1zLkewOVg{KM7:TR?=	NHK0e3VUSU6JUlXS
KURAMOCHI	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEKxWXNKSzVyPUGuO\|g6OTFizszN	MU\TRW5IWkWU
TE-8	M1PwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTFwOECzOlgh\|ryP	NHPONI5USU6JUlXS
NCI-H1304	NW[0[nBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknnTWM2OD1zLkizNFc{KM7:TR?=	MY\TRW5IWkWU
A101D	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1uyVWlEPTB;MT64O\|M6PSEQvF2=	MnS4V2FPT1KHUh?=
SCLC-21H	M3TIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTFwOUewOVch\|ryP	NInsWZJUSU6JUlXS
GB-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLKVZRKSzVyPUKuNFE3PDdizszN	M2SzZnNCVkeURWK=
KARPAS-45	NFP4Z5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PmRmlEPTB;Mj6wNlY2PCEQvF2=	MUTTRW5IWkWU
ATN-1	NUfxd2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fRO2lEPTB;Mj6wNlg2QCEQvF2=	MlS5V2FPT1KHUh?=
NCI-H720	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITVNppKSzVyPUKuNFYzPDRizszN	NEnR[JhUSU6JUlXS
RPMI-6666	NXP2dnlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXztNm9qUUN3ME2yMlE3OjB5IN88US=>	NG\ucINUSU6JUlXS
NB17	NFvmelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoL2TWM2OD1{LkK5Nlch\|ryP	NV64Wm0zW0GQR2LFVi=>
IST-SL1	NEP2T2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml2xTWM2OD1{LkK5O\|Y2KM7:TR?=	NUHLSmxnW0GQR2LFVi=>
SH-4	NE\qT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfIPYxNUUN3ME2yMlMzPDZ7IN88US=>	MkP0V2FPT1KHUh?=
K5	NUS0dIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PHTGlEPTB;Mj60NFMyQSEQvF2=	NWrLPG9iW0GQR2LFVi=>
OVCAR-4	M1K2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlr4TWM2OD1{LkS2NVMh\|ryP	NHXsU3FUSU6JUlXS
ACN	M3\kdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTJwNUCyNVMh\|ryP	MUXTRW5IWkWU
TGW	NW\KNWY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTtTWM2OD1{Lk[1PFMzKM7:TR?=	NI\keoFUSU6JUlXS
NCI-H2107	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHCTWM2OD1{LkizO\|EyKM7:TR?=	MmiwV2FPT1KHUh?=
NCI-H82	MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\TS2lEPTB;Mj64N\|g{QCEQvF2=	MlfyV2FPT1KHUh?=
SK-N-FI	MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTJwOE[4Olgh\|ryP	NXHOTplZW0GQR2LFVi=>
LB1047-RCC	NIXTVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTJwOEixNlYh\|ryP	M1nsRnNCVkeURWK=
LU-134-A	M3Xn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonHTWM2OD1{Lki5NlYh\|ryP	NXHwc\|A4W0GQR2LFVi=>
NCI-H209	Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG[zS4tKSzVyPUKuPVEzPTNizszN	MnexV2FPT1KHUh?=
NOMO-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7teHhWUUN3ME2zMlAzOjd2IN88US=>	MU\TRW5IWkWU
RH-1	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPBTWM2OD1\|LkG3NlkyKM7:TR?=	NGi2fmZUSU6JUlXS
LOUCY	NXKyUpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jrTGlEPTB;Mz6xPFY6OyEQvF2=	NVTtOY5TW0GQR2LFVi=>
TE-9	NE\oUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XkfmlEPTB;Mz6yOlc{PiEQvF2=	MlHaV2FPT1KHUh?=
PF-382	NW\VSItkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XybWlEPTB;Mz6zOVc4QCEQvF2=	MmLqV2FPT1KHUh?=
RPMI-8402	NVO0WFFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M36wUWlEPTB;Mz61PFYxOyEQvF2=	NEi5XlJUSU6JUlXS
HEL	Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2exRWlEPTB;Mz62N\|Ih\|ryP	NXzMbJdTW0GQR2LFVi=>
NOS-1	M4fyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3nWWNKSzVyPUOuPFQ4PTRizszN	M1u1WHNCVkeURWK=
ES1	NWLCN2xwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHSUJVwUUN3ME2zMlkzOjl\|IN88US=>	MkTHV2FPT1KHUh?=
NCI-H2171	NVPrb4pTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7zTWM2OD1\|LkmyOFI{KM7:TR?=	NXLQbIk2W0GQR2LFVi=>
NCI-H747	MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfZTWM2OD1\|Lkm0NlIyKM7:TR?=	NH7QPFVUSU6JUlXS
MHH-NB-11	M3vwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HCU2lEPTB;Mz65OVMyOiEQvF2=	MlO0V2FPT1KHUh?=
MZ1-PC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\YcodOUUN3ME2zMlk6OjRizszN	NHXjfpFUSU6JUlXS
MMAC-SF	M3rW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTRwMEK0Olch\|ryP	NGfTeplUSU6JUlXS
NMC-G1	NEnFWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzTUYxKSzVyPUSuNlI4OjNizszN	MnvJV2FPT1KHUh?=
SW872	NHeyVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjs[pVtUUN3ME20MlM1OzRizszN	MUXTRW5IWkWU
TE-12	Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4f6TGlEPTB;ND61OlM6PCEQvF2=	M{jMd3NCVkeURWK=
LU-139	NUW5WmxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTRwNkG4N\|Uh\|ryP	MorTV2FPT1KHUh?=
HC-1	MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nsfGlEPTB;ND62PVQ6PCEQvF2=	M1T1V3NCVkeURWK=
COR-L279	NI\PTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrGUo9KSzVyPUSuO\|U5QTFizszN	M1;xdnNCVkeURWK=
SF268	NYHCZYwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrYOmlKSzVyPUSuO\|k6OTZizszN	M135enNCVkeURWK=
MC-CAR	NIHI[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\reHRXUUN3ME21MlA3PzV5IN88US=>	NVvFSI82W0GQR2LFVi=>
TK10	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rX[mlEPTB;NT6zOVQ3QSEQvF2=	Ml[zV2FPT1KHUh?=
TE-1	MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LCXmlEPTB;NT60PVAxPCEQvF2=	NUW2Xo9IW0GQR2LFVi=>
NCI-H2126	Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTVwNkS1O\|Qh\|ryP	M{fpZ3NCVkeURWK=
Daudi	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2j2eGlEPTB;NT62PVEzKM7:TR?=	M4S4dnNCVkeURWK=
NCI-H1648	NFvkOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDXNYFKSzVyPUWuPFE1PTRizszN	NFvWenBUSU6JUlXS
OS-RC-2	NVixN5g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jLbGlEPTB;NT65PFU6PyEQvF2=	MVfTRW5IWkWU
DJM-1	M4PjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTZwM{S2OlYh\|ryP	MY\TRW5IWkWU
LS-1034	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGG1UFNKSzVyPU[uO\|U3PiEQvF2=	NXT3fmJsW0GQR2LFVi=>
NCI-H1581	MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\XXWlEPTB;Nj63PFQxPSEQvF2=	NI\NNJRUSU6JUlXS
UACC-257	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWn5VHcxUUN3ME23MlA1PTF{IN88US=>	Mo\BV2FPT1KHUh?=
KM-H2	MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTdwMUi0OVch\|ryP	NV7yd\|BOW0GQR2LFVi=>
NCI-H1436	NIntUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTdwNkm5N\|Ih\|ryP	Ml;5V2FPT1KHUh?=
IA-LM	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7qcmNKSzVyPUeuPFU6KM7:TR?=	M2THRXNCVkeURWK=
NCI-H526	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrSTlRKSzVyPUiuNlU3OzdizszN	M133PXNCVkeURWK=
GCIY	NYXKWJozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:w[otKSzVyPUiuN\|Y6PjVizszN	MmHIV2FPT1KHUh?=
CP67-MEL	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvLWVcxUUN3ME24MlU{OjZizszN	M1y2bHNCVkeURWK=
KALS-1	NV35bXZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLkTWM2OD16LkizPFUyKM7:TR?=	NX;LRlVOW0GQR2LFVi=>
NCI-H1770	M4DQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7MfVNKSzVyPUiuPVAzPjVizszN	NF7kVnFUSU6JUlXS
8-MG-BA	MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULkTmxIUUN3ME25MlMzQDR2IN88US=>	MkHLV2FPT1KHUh?=
KY821	M4[1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTkR3pNUUN3ME25Mlc4PDh2IN88US=>	MYnTRW5IWkWU
SNB75	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjEVIVKSzVyPUGwMlA4PiEQvF2=	M4LqenNCVkeURWK=
NCCIT	NX7rOVBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTFzLkC1PFIh\|ryP	M3zrN3NCVkeURWK=
SJSA-1	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fPfGlEPTB;MUGuNlg6OSEQvF2=	MXLTRW5IWkWU
LB373-MEL-D	NIq1OYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HvZ2lEPTB;MUGuN\|gzPyEQvF2=	MWrTRW5IWkWU
TALL-1	M{XSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTFzLkSwOVgh\|ryP	MXPTRW5IWkWU
NB69	NWG5SJFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHuweZdKSzVyPUGxMlc4ODVizszN	M1iy[HNCVkeURWK=
NCI-H1355	Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPsdpVKSzVyPUGxMlk1OjZizszN	MWHTRW5IWkWU
DMS-153	NEjGU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4W4WmlEPTB;MUKuNFQzPiEQvF2=	MYLTRW5IWkWU
OPM-2	NF\qb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLNTWM2OD1zMj6xOVk3KM7:TR?=	NHLQVoxUSU6JUlXS
NB1	NUX3SmVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTyWpFiUUN3ME2xNk4zQSEQvF2=	Mm\6V2FPT1KHUh?=
A3-KAW	NYXXeVZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTVRY1tUUN3ME2xNk4{OjN4IN88US=>	NV3RWWs6W0GQR2LFVi=>
NCI-H1882	NYfUSVhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVz1foJPUUN3ME2xNk41ODZ4IN88US=>	MojnV2FPT1KHUh?=
KG-1	MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfHWlNKSzVyPUGyMlY2PDVizszN	MYXTRW5IWkWU
LC4-1	M33XSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LRU2lEPTB;MUKuO\|cxPiEQvF2=	M4L5SnNCVkeURWK=
HCE-T	NUi2e\|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;jTWM2OD1zMz6wNFQ6KM7:TR?=	MX3TRW5IWkWU
NEC8	M1Wwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjlTWM2OD1zMz6xNFM5KM7:TR?=	NULOb2ZGW0GQR2LFVi=>
IST-MEL1	M2ewZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnuSIxDUUN3ME2xN{42Pzh6IN88US=>	NHrv[HpUSU6JUlXS
EW-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi3fplKSzVyPUGzMlc1ODJizszN	NWjUeVdrW0GQR2LFVi=>
CTB-1	M161[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHe1fHpKSzVyPUG0MlA{OjlizszN	MXXTRW5IWkWU
LS-123	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXXV5RKSzVyPUG0MlE2QDhizszN	NUPzcWFQW0GQR2LFVi=>
NCI-H1417	M{Dtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnybHhSUUN3ME2xOE4{ODV{IN88US=>	NFXmeo9USU6JUlXS
MZ7-mel	M{DjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjkTndKSzVyPUG0MlQ1OzNizszN	MkfiV2FPT1KHUh?=
JiyoyeP-2003	M1XxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrpdoc5UUN3ME2xOU43OzJ4IN88US=>	M1fSbHNCVkeURWK=
ES6	M{DDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjH[2pUUUN3ME2xOk4zOzZzIN88US=>	NGq2XIxUSU6JUlXS
HH	NX33cIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;4TWM2OD1zNz6xPVY{KM7:TR?=	NFPDco1USU6JUlXS
SF539	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTF5Lkm5NlIh\|ryP	MXjTRW5IWkWU
Calu-6	Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnpTY9{UUN3ME2xPU4zOzlizszN	NFLRPXlUSU6JUlXS
SK-MM-2	NEfzN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrFVW9KSzVyPUG5MlU2PSEQvF2=	NF7veIlUSU6JUlXS
IST-MES1	M{TOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTF7Lk[2OlMh\|ryP	M4fXUnNCVkeURWK=
GI-ME-N	MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzrTWM2OD1zOT64NlI4KM7:TR?=	M2PZU3NCVkeURWK=
CAL-148	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDmcGdKUUN3ME2yNE46QTN2IN88US=>	M1:1fXNCVkeURWK=
EVSA-T	NUDOPGlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TUXWlEPTB;MkGuNVQ6QSEQvF2=	NEi4SXlUSU6JUlXS
LP-1	MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDVTWM2OD1{MT6zOFMzKM7:TR?=	MWDTRW5IWkWU
BOKU	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjBTWM2OD1{MT60OVM{KM7:TR?=	MmP6V2FPT1KHUh?=
KLE	NWXLS2JzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLjTWM2OD1{Mj6xPVA{KM7:TR?=	Ml\RV2FPT1KHUh?=
LB831-BLC	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPZ[GZJUUN3ME2yOU4yPTJ4IN88US=>	M{jkR3NCVkeURWK=
NCI-H889	MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nEdmlEPTB;MkWuNVk{OSEQvF2=	MUnTRW5IWkWU
REH	NXO5Nld5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mof4TWM2OD1{NT60OlcyKM7:TR?=	Mor2V2FPT1KHUh?=
KP-N-RT-BM-1	MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M322V2lEPTB;MkWuOFc2OiEQvF2=	M1qwUHNCVkeURWK=
MPP-89	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{G2VGlEPTB;MkWuOVMyPCEQvF2=	M3n2PHNCVkeURWK=
no-11	M2PmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2m3T2lEPTB;MkWuO\|Q4KM7:TR?=	M4LYVnNCVkeURWK=
NCI-H748	Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGT6fJJKSzVyPUK1Mlc3OjdizszN	NHX2S49USU6JUlXS
LB2518-MEL	NInmbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DsZmlEPTB;MkeuNVc4OyEQvF2=	MonEV2FPT1KHUh?=
TGBC1TKB	NHjHS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHUTWM2OD1{Nz61OVg2KM7:TR?=	MmL2V2FPT1KHUh?=
MHH-PREB-1	MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{ixPGlEPTB;MkiuNFc{PCEQvF2=	M3Hhe3NCVkeURWK=
MZ2-MEL	NV7QV285T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fpTmlEPTB;MkiuOlE1OyEQvF2=	M4HVWHNCVkeURWK=
U-266	NWjtSJU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTJ6Lk[zOlYh\|ryP	NHP2NGdUSU6JUlXS
SNU-C1	M1TVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXxTWM2OD1{OD65OFMh\|ryP	NXLxXllqW0GQR2LFVi=>
SW962	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XMUWlEPTB;M{CuNlc1PyEQvF2=	MVXTRW5IWkWU
Raji	M{TIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\qSVdKSzVyPUOwMlU2QTJizszN	M1jQZXNCVkeURWK=
KNS-42	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInTVlBKSzVyPUOwMlg6PTZizszN	NGXuXXNUSU6JUlXS
LB996-RCC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fOfWlEPTB;M{GuNVcxOiEQvF2=	MoqwV2FPT1KHUh?=
CHP-126	NV31NGg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkm1TWM2OD1\|MT6xPVg1KM7:TR?=	M{XlOHNCVkeURWK=
RXF393	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXJTWM2OD1\|Mj60PVch\|ryP	NGjBOnZUSU6JUlXS
COLO-684	MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfGVpBIUUN3ME2zNk43PDN6IN88US=>	MXLTRW5IWkWU
A704	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIr0S2RKSzVyPUOzMlU2OzhizszN	MYTTRW5IWkWU
A253	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\rfo83UUN3ME2zN{42QDV{IN88US=>	MkPTV2FPT1KHUh?=
KNS-81-FD	NFHiZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HlfmlEPTB;M{SuOVQ2PiEQvF2=	NWruT\|RLW0GQR2LFVi=>
TE-441-T	M1z5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfYTWM2OD1\|ND62N\|cyKM7:TR?=	NYPEWlhOW0GQR2LFVi=>
HCC2157	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;CeWlEPTB;M{WuOFYyQSEQvF2=	MVvTRW5IWkWU
ES3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTN4Lk[3OUDPxE1?	MUDTRW5IWkWU
NCI-H1155	NUHWb5VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVW5cZN[UUN3ME2zO{45OTVizszN	MXHTRW5IWkWU
SNU-C2B	NV\k[2NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXreGIzUUN3ME2zPE4yPjV2IN88US=>	M{P4NHNCVkeURWK=
JAR	NHPSU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVeyOJBnUUN3ME2zPE4zPDR7IN88US=>	Mn7IV2FPT1KHUh?=
GDM-1	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTN6LkmxNVYh\|ryP	M4HkTXNCVkeURWK=
KU812	NGnnV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfyUmdKSzVyPUSxMlUxPyEQvF2=	MYfTRW5IWkWU
BC-1	MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PJZmlEPTB;NEKuOlc{OSEQvF2=	M{fMfnNCVkeURWK=
GI-1	NXjXVIVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LqTGlEPTB;NEKuPVE6OiEQvF2=	Ml;VV2FPT1KHUh?=
NCI-H1694	NFzvOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXDTWM2OD12ND65OFczKM7:TR?=	M2\zSXNCVkeURWK=
DG-75	NX7sZoZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLxTWM2OD12NT6xOVc4KM7:TR?=	NX61PZd1W0GQR2LFVi=>
COR-L88	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\Le2lEPTB;NEWuNlc4QCEQvF2=	NIr5W3lUSU6JUlXS
LS-513	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml36TWM2OD12NT65NVU3KM7:TR?=	M13jcXNCVkeURWK=
HD-MY-Z	M2XpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTR4LkS2NVIh\|ryP	MnrGV2FPT1KHUh?=
L-363	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1S1OWlEPTB;NE[uPFgyKM7:TR?=	Mn7rV2FPT1KHUh?=
TE-6	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TRbGlEPTB;NEiuOFQ3KM7:TR?=	M{\pXnNCVkeURWK=
NCI-H345	NWHJVVA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHHTWM2OD12OD60Olgh\|ryP	NYnUeY1ZW0GQR2LFVi=>
TE-5	NVjG[5ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3y4RWlEPTB;NEmuO\|EyQCEQvF2=	M1j5WXNCVkeURWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DLK / p-MKK7 / MKK7 / p-JNK / JNK ; PubMed: 23431148 Proc Natl Acad Sci U S A Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. p-AURKA / AURKA / Survivin ; PubMed: 28218735 Oncogenesis BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. YAP; PubMed: 31160567 Cell Death Dis Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; PubMed: 21600017 J Transl Med NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.	23431148 28218735 31160567 21600017
Immunofluorescence	α-tubulin / Aurora-A ; PubMed: 21600017 J Transl Med The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.	21600017
Growth inhibition assay	Cell viability; PubMed: 21600017 J Transl Med VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, p < 0.05, *p < 0.01, compared to control.	21600017

体内研究

VX-680作用于人类AML(HL-60)移植瘤模型明显降低肿瘤尺寸。VX-680按75 mg/kg剂量给药实验鼠,每天腹腔注射两次，持续13天,与对照组相比，平均肿瘤体积下降达98%。肿瘤体积比实验之前初始体积小很多。按12.5 mg/kg剂量每天给药两次，肿瘤生长也明显降低，这种作用存在剂量依赖性。VX-680耐受性很好，只有在使用高剂量时可以观察到实验动物体重稍微降低。通过比较cisplatin,按5.4 mg/kg剂量给药，每四天腹腔注射一次，一共进行三次，抑制肿瘤生长只达9%。VX-680作用于胰脏和结肠移植瘤，也引起肿瘤衰退。VX-680静脉注射给药携带HCT116肿瘤的实验鼠，显示很强的抗癌活性。使用高剂量VX-680(每小时2 mg/kg)处理，明显提高效果，比实验钱的初始肿瘤平均尺寸下降56%。^[1]

激酶实验： ^[3]	- 合并激酶抑制实验: 丙酮酸激酶/乳酸脱氢酶催化NADH的氧化，伴随着ATP的消耗，观察340 nm 处吸光值的降低。反应包括100 mM Tris (pH 为 8), 10 mM MgCl₂, 2.2 mM ATP, 1 mM磷酸烯醇丙酮酸, 0.6 mg/ml NADH, 75 ml丙酮酸激酶, 105 ml 乳酸脱氢酶,和0.5 mM 基底肽(序列为EAIYAAPFAKKK)。加入足够的激酶开始反应，反应的激酶浓度达到30 nM，用微量滴定板分光光度计在30^oC进行30分钟，观察吸收率的降低。通过加入3.75 μl 溶于100% DMSO的VX-680 或单独DMSO，获得抑制常数。按如下公式计算K_i值，K_i = IC50/(1+[S]/K_d),[S]=[ATP]=2.2 mM, K_d=70 μM。假定作用于野生型和H396P Abl 激酶域的K_d(ATP)为70 μM，计算以上各值。
细胞实验： ^[2]	- 合并 Cell lines: CAL-62细胞 Concentrations: 5-500 nM Incubation Time: 4天 Method: 对照组CAL-62细胞培养在二甲亚砜和DMSO中，实验组加入500 nM VX-680，处理1到5天。加入不同浓度(5到500 nM) Aurora抑制剂处理不同ATC细胞4天，用来测定VX-680作用于细胞增殖的剂量依赖性。细胞在温育结束前加30 mM BrdU标记，脉冲2小时。通过比色免疫分析使用细胞增殖ELISA试剂盒分析BrdU的合并率。通过比较VX-680处理的细胞和对照组细胞得到结果， (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 右侧腋窝处皮下注射107 HL-60白血病细胞的雌性无胸腺NCr-nu鼠 Dosages: 50 mg/kg, 75 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

[4] Cheetham GM, et al. Cancer Lett. 2007, 251(2), 323-329.

- 合并

溶解度 (25°C)

体外	DMSO	93 mg/mL (200.17 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+2% Tween 80+ddH2O	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Tozasertib (VX-680, MK-0457) SDF

分子量	464.59
化学式	C₂₃H₂₈N₈OS
CAS号	639089-54-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

泛Aurora Kinase抑制剂

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
泛Aurora Kinase抑制剂

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
活性最高的Aurora Kinase抑制剂

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
用于临床的Aurora Kinase抑制剂

Alisertib (MLN8237) : Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.
经典的Aurora Kinase抑制剂

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

研究领域

产品类型

定制您的化合物库

Tozasertib (VX-680, MK-0457)

客户使用Selleck生产的Tozasertib (VX-680, MK-0457)发表文献88篇：

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Tozasertib (VX-680, MK-0457) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品